|
🐜
|
DOSE ESCALATION WITH THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY AFFECTS THE OUTCOME IN PROSTATE CANCER
10 auth.
M. Zelefsky,
StevenA Leibel,
P. Gaudin,
G. Kutcher,
N. Fleshner,
E. Venkatramen,
...
V. Reuter,
W. Fair,
C. Ling,
Z. Fuks
|
9 |
1998 |
9
🐜
|
|
🐜
|
Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.
11 auth.
M. Zelefsky,
S. Leibel,
P. Gaudin,
G. Kutcher,
N. Fleshner,
E. Venkatramen,
...
V. Reuter,
W. Fair,
C. Ling,
Z. Fuks,
P. Walsh
|
8 |
1999 |
8
🐜
|
|
🐜
|
Long term tolerance of high dose three‐dimensional conformal radiotherapy in patients with localized prostate carcinoma
8 auth.
M. Zelefsky,
D. Cowen,
Z. Fuks,
M. Shike,
C. Burman,
Andrew Jackson,
...
E. Venkatramen,
S. Leibel
|
8 |
1999 |
8
🐜
|
|
🐜
|
An analysis of late urinary toxicity based upon urethra dose volume histograms after transperineal permanent interstitial iodine 125 prostate brachytherapy
7 auth.
Y. Yamada,
M. Kim,
G. Cohen,
M. Zaider,
E. Venkatramen,
K. Wallner,
...
M. Zelefsky
|
2 |
2000 |
2
🐜
|
|
🐜
|
O-075 Malignant pleural mesothelioma (MPM): New predictors ofsurvival and an analysis of the impact of current treatment
10 auth.
R. Flores,
M. Zakowski,
E. Venkatramen,
L. Krug,
K. Rosenzweig,
J. Dycoco,
...
Cindy B. Yeoh,
Catherine Lee,
M. Bains,
V. Rusch
|
1 |
2005 |
1
🐜
|
